Transposon Mutagenesis for Host-Target and Drug Discovery in Infectious Disease
传染病宿主靶标和药物发现的转座子诱变
基本信息
- 批准号:8883359
- 负责人:
- 金额:$ 49.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAntiviral AgentsAntiviral resistanceArenavirusBioinformaticsBioterrorismCandidate Disease GeneCell DeathCell LineCellsChronicCommunicable DiseasesDataDrug resistanceEbola Hemorrhagic FeverEbola virusFilovirusFrankfurt-Marburg Syndrome VirusGene ExpressionGenerationsGenesGenetic ScreeningGoalsHealthcareHost resistanceImmuneImmune systemImmunityIndividualInfectionInfectious AgentIntegration Host FactorsLeadLibrariesMediatingMutagenesisMutationOutcomePathway interactionsPattern recognition receptorPhaseRNA VirusesResistanceSignal PathwaySiteSystemTestingTherapeuticTherapeutic InterventionUp-RegulationVariantVesicular stomatitis Indiana virusViralViral Hemorrhagic FeversVirusVirus Diseasesbasecare burdenchemokinechemotherapycombatcytokinedrug discoverygenome-widemutantnovelnovel therapeuticspreventpromoterresearch studyresistance generesponsescreeningsmall moleculesuccess
项目摘要
Although both acute and chronic viral infections remain a major health care
burden, the therapeutic options are limited. Some of the most concerning of the viral
infections include those caused by the Filoviruses and the Arenaviruses. These RNA
viruses cause severe hemorrhagic fevers that are often lethal. Early defense against all
viruses is mediated by the innate immune system and the responses triggered by
pattern recognition receptors that induce the cytokines and chemokines that orchestrate
much of the local and systemic anti-viral defenses. However, in addition to these well-
defined innate immune signaling pathways, less well-understood cell autonomous
factors also contribute to protect the host from and during viral infection. Based on
emerging data and our preliminary studies, we hypothesize that an important strategy of
host resistance against viruses is the upregulation of `restriction factors' that prevent viral
entry, restrict the ability of viruses to infect or replicate in host cells or increase the ability
of cells to withstand viral-induced cytopathy. However, although these restriction factors
are likely to provide a wealth of new targets for therapeutic intervention, the identities of
such cell-autonomous host factors that protect against viruses are largely unknown.
Here we propose to utilize and further optimize a novel unbiased screening approach
using transposon mutagenesis. This strategy relies three steps: (i) piggyBac transposon
mutagenesis to generate a library of mutagenized cells, (ii) selection of mutant clones
resistant to viral-induced cell death and (iii) sequencing to identify transposon insertions
sites and candidate genes that contribute to protect the mutant cells from the selection
agent. In the R21 phase of this proposal we aim to further develop and utilize this
approach for identification of antiviral restriction factors. Additionally, in the R33 phase
we propose to both validate our new host targets using native virus as well as modify the
transposon system for drug discovery.
虽然急性和慢性病毒感染仍然是一个主要的卫生保健
负担,治疗选择有限。一些最令人担忧的病毒
感染包括由丝状病毒和沙粒病毒引起的感染。这些RNA
病毒引起严重的出血热,常常是致命的。早期防御所有
病毒是由先天免疫系统介导的,
诱导细胞因子和趋化因子的模式识别受体,
局部和全身的抗病毒防御系统。但是,除了这些好的--
明确的先天免疫信号通路,不太清楚的细胞自主
这些因子也有助于保护宿主免受病毒感染和在病毒感染期间保护宿主。基于
新兴的数据和我们的初步研究,我们假设,一个重要的战略,
宿主对病毒的抗性是“限制因子”的上调,
进入,限制病毒在宿主细胞中感染或复制的能力,或增加病毒在宿主细胞中感染或复制的能力。
抵抗病毒引起的细胞病变。尽管这些限制因素
可能为治疗干预提供大量新靶点,
这种保护免受病毒侵害的细胞自主宿主因子在很大程度上是未知的。
在这里,我们建议利用和进一步优化一种新的无偏筛选方法
使用转座子诱变。该策略依赖于三个步骤:(i)piggyBac转座子
诱变以产生诱变细胞文库,(ii)选择突变克隆
对病毒诱导的细胞死亡具有抗性,和(iii)测序以鉴定转座子插入
有助于保护突变细胞免受选择的位点和候选基因
剂在本提案的R21阶段,我们的目标是进一步开发和利用这一点,
用于鉴定抗病毒限制因子的方法。此外,在R33阶段
我们建议使用原生病毒验证我们的新主机目标,并修改
转座子系统用于药物发现。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Adam Lacy-Hulbert其他文献
Adam Lacy-Hulbert的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Adam Lacy-Hulbert', 18)}}的其他基金
LITAF regulation of cell death and inflammatory responses
LITAF 调节细胞死亡和炎症反应
- 批准号:
10886166 - 财政年份:2023
- 资助金额:
$ 49.99万 - 项目类别:
Immune Signatures and Clinical Outcomes in Acute Pancreatitis
急性胰腺炎的免疫特征和临床结果
- 批准号:
10568011 - 财政年份:2023
- 资助金额:
$ 49.99万 - 项目类别:
alpha v integrin regulation of B cell tolerance
B 细胞耐受的 α v 整合素调节
- 批准号:
10294130 - 财政年份:2020
- 资助金额:
$ 49.99万 - 项目类别:
Identification of Host Drug Development Targets in Influenza Using Transposon Mutagenesis
使用转座子诱变鉴定流感宿主药物开发靶点
- 批准号:
8956296 - 财政年份:2015
- 资助金额:
$ 49.99万 - 项目类别:
Identification of Host Drug Development Targets in Influenza Using Transposon Mutagenesis
使用转座子诱变鉴定流感宿主药物开发靶点
- 批准号:
9089858 - 财政年份:2015
- 资助金额:
$ 49.99万 - 项目类别:
Transposon Mutagenesis for Host-Target and Drug Discovery in Infectious Disease
传染病宿主靶标和药物发现的转座子诱变
- 批准号:
8490300 - 财政年份:2012
- 资助金额:
$ 49.99万 - 项目类别:
Dendritic Cell Control of Intestinal T Cell Responses
树突状细胞控制肠道 T 细胞反应
- 批准号:
8868105 - 财政年份:2012
- 资助金额:
$ 49.99万 - 项目类别:
Dendritic Cell Control of Intestinal T Cell Responses
树突状细胞控制肠道 T 细胞反应
- 批准号:
8372489 - 财政年份:2012
- 资助金额:
$ 49.99万 - 项目类别:
Transposon Mutagenesis for Host-Target and Drug Discovery in Infectious Disease
传染病宿主靶标和药物发现的转座子诱变
- 批准号:
8391403 - 财政年份:2012
- 资助金额:
$ 49.99万 - 项目类别:
Dendritic Cell Control of Intestinal T Cell Responses
树突状细胞控制肠道 T 细胞反应
- 批准号:
8843114 - 财政年份:2012
- 资助金额:
$ 49.99万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 49.99万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 49.99万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 49.99万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 49.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 49.99万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 49.99万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 49.99万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 49.99万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 49.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 49.99万 - 项目类别:














{{item.name}}会员




